STOCK TITAN

Alkermes plc (ALKS) DEF 14A Filings

ALKS NASDAQ

Here are the DEF 14A proxy statements from Alkermes Inc. plc (ALKS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ALKS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALKS filings page.

Rhea-AI Summary

Alkermes plc is soliciting proxies for its 2026 annual meeting on May 20 in Dublin, where shareholders will elect directors, cast advisory votes on executive pay and auditor ratification, and consider approval of the amended 2018 stock plan and renewed Irish share issuance and pre‑emption waivers.

The proxy highlights 2025 performance, including approximately $1.48 billion in revenue and about $1.2 billion in proprietary product net sales, plus GAAP net income of roughly $242 million and Adjusted EBITDA of $394 million. It notes the completed acquisition of Avadel Pharmaceuticals, advances in the orexin 2 pipeline, and strong growth in VIVITROL, LYBALVI and ARISTADA. The filing also details CEO Richard Pops’ planned July 2026 retirement, Blair Jackson’s appointment as next CEO, extensive board refreshment and independence, pay‑for‑performance incentive design, and expanded ESG and shareholder‑engagement initiatives.